Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

Cardio Casesadult-congenital-heart-disease

Cardio Cases · adult-congenital-heart-disease

Secundum ASD with pulmonary arterial hypertension — case discussion

Practice case: a 56-year-old woman with a secundum ASD and PAH; invasive PVR, why closure is deferred, the ACC/AHA 2025 and ESC treat-and-repair rows, closure after PAH therapy (fenestrated closure under ESC 2020 and ACC/AHA 2025, shunt closure under ESC/ERS 2022 Recommendation Table 18), and follow-up.

practice case discussion (not a real patient)3 min readVerification in progress

Target exams

  • EECC
  • ABIM Cardiovascular Disease Certification
On this page
Study tools

Target exams

  • EECC
  • ABIM Cardiovascular Disease Certification
Prompt
A 56-year-old woman with a secundum ASD has declining exercise tolerance, palpitations and raised pulmonary artery pressure on echocardiography.

Presentation

Practice case (not a real patient). A 56-year-old woman in Brisbane has 3 years of declining exercise tolerance, exertional breathlessness and palpitations.[1] She has fixed splitting of the second heart sound and a systolic pulmonary flow murmur; the ECG shows incomplete right bundle branch block and right-axis deviation.[1] Transthoracic echocardiography shows a secundum ASD with RV enlargement and increased stroke volume, normal LV function with no LV disease, and a calculated systolic pulmonary artery pressure of 62 mmHg.[1]

Step 1 — Define the defect and the pulmonary circulation

Discussion:

  • ESC 2020 requires catheterisation to determine PVR when the calculated systolic pulmonary artery pressure is over 40 mmHg, and makes invasive PVR measurement mandatory with non-invasive signs of raised pressure (Class I, Level C).[1]
  • ACC/AHA 2025 recommends CMR, TOE or cardiac CT to define defect size, morphology, rim anatomy and pulmonary venous connections (COR 1, LOE B-NR), and assessment for PAH to guide therapy and suitability for repair (COR 1, LOE C-EO).[2]
  • Catheterisation shows mean pulmonary artery pressure 34 mmHg, wedge pressure 10 mmHg, PVR 6.2 WU and Qp:Qs 1.9; she has PAH by the ACC/AHA definition (mean PA pressure over 20 mmHg, PVR over 2 Wood units, wedge 15 mmHg or less).[2]
  • Six-minute walk testing shows no desaturation; ESC 2020 says exercise testing should be done in PAH to exclude it.[1]

Step 2 — Close now?

Discussion:

  • Not now. ESC 2020 says that with PVR of 5 WU or more improvement is unlikely and complete closure is likely to make the outcome worse; vasoreactivity testing is not recommended for the decision.[1]
  • ACC/AHA 2025 recommends that adults with an unrepaired ASD and PAH undergo risk assessment and management in consultation with pulmonary hypertension specialists, to improve outcomes (COR 1, LOE B-NR).[2]
  • Her profile matches the ACC/AHA row in which, with Qp:Qs of 1.5 or more, RV dilation, PVR 5–8 Wood units and no significant LV disease, closure can be beneficial if PVR under 5 Wood units can be achieved with targeted PAH therapy (COR 2a, LOE B-NR).[2]
  • Targeted PAH therapy is started; ESC 2020 says it appears safer to treat PAH, re-evaluate haemodynamics and consider fenestrated closure only if PVR falls below 5 WU with a significant left-to-right shunt.[1]

Step 3 — Reassessment

Discussion:

  • After treatment, repeat catheterisation shows PVR 4.1 WU with Qp:Qs still over 1.5.[1]
  • ESC 2020: with PVR of 5 WU or more that falls below 5 WU after targeted PAH treatment and a significant left-to-right shunt (Qp:Qs over 1.5), fenestrated closure may be considered (Class IIb, Level C).[1]
  • The newer ESC/ERS 2022 row (Recommendation Table 18, for a pulmonary-to-systemic flow ratio over 1.5:1): with ASD and PVR over 5 WU that declines to under 5 WU with PAH treatment, shunt closure may be considered (Class IIb, Level C), with a multiparametric decision rather than numbers alone.[3]
  • Under ACC/AHA 2025, the condition of its COR 2a row is now met: PVR under 5 Wood units has been achieved with targeted PAH therapy, so closure can be beneficial to improve medium-term functional status.[2]
  • ACC/AHA 2025: for an adult with ASD and PAH for whom closure is indicated, fenestrated repair can be considered to improve functional class and clinical outcomes (COR 2b, LOE B-NR); closure with raised PVR does not remove the need for continued PAH therapy and specialised care.[2]

Step 4 — After closure

Discussion:

  • Follow-up should assess residual shunt, RV size and function, TR and pulmonary pressure by echocardiography, and arrhythmias by history, ECG and, only if indicated, Holter monitoring (ESC 2020).[1]
  • Repair at adult age, particularly over 40, and raised pulmonary pressure call for regular follow-up, including in specialised ACHD centres (ESC 2020).[1]
  • ESC 2020 reports that in patients who undergo ASD closure aged over 40, as she would, the prevalence of atrial arrhythmias is up to 40–60%.[1]
References3ShowHide
  1. [1]Baumgartner H, et al. 2020 ESC Guidelines for the management of adult congenital heart disease. Eur Heart J, 2021.PMID 32860028
  2. [2]Gurvitz M, et al. 2025 ACC/AHA/HRS/ISACHD/SCAI Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 2026.PMID 41411375
  3. [3]Humbert M, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J, 2023.PMID 36028254
PreviousType 2 diabetes and decompensated heart failure on pioglitazone — case discussionprevention-risk